Welcome to our dedicated page for Unicycive Therapeutics SEC filings (Ticker: UNCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unicycive Therapeutics filings document the regulatory, financing, governance, and operating disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on kidney disease therapies. Form 8-K reports furnish financial results and business updates, including disclosures related to oxylanthanum carbonate, NDA activity, manufacturing matters, and the company’s cash and capital resources.
The filing record also covers common stock registered on the Nasdaq Capital Market, emerging growth company status, at-the-market equity sales under a shelf registration statement, and board and executive-governance matters. Proxy materials document director elections, auditor ratification, stockholder voting mechanics, and annual meeting procedures, while other current reports address securities litigation risk tied to public statements about the OLC program.
Octagon Capital Advisors LP and related funds and principal Ting Jia report beneficial ownership of 1,000,000 shares of Unicycive Therapeutics, Inc. (UNCY), representing 7.8% of the outstanding common stock based on 12,768,239 shares outstanding as reported by the issuer. Octagon is the investment manager of the funds and Mr. Jia is the managing member of Octagon, and by virtue of those relationships Octagon and Mr. Jia may be deemed to beneficially own the shares held by the funds.
The filing discloses that the reported holdings are held with shared voting and dispositive power rather than sole power. The ownership is allocated as 650,000 shares (5.1%) held by Octagon Investments Master Fund LP and 350,000 shares (2.7%) held by Octagon Private Opportunities Fund II LP. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Unicycive Therapeutics (NASDAQ: UNCY) has announced a 1-for-10 reverse stock split effective June 18, 2025, at 4:01 PM ET. The company's common stock began trading on a split-adjusted basis on the Nasdaq Capital Market on June 20, 2025, maintaining its "UNCY" symbol but with a new CUSIP number.
Key details of the reverse split:
- Reduced outstanding shares from 126,409,281 to approximately 12,768,239
- No fractional shares issued - fractional interests rounded up to the next whole share
- Proportionate adjustments made to stock options, warrants, and Series A-2 prime preferred stock conversion prices
- No change to authorized shares or par value
- No material change to stockholders' percentage ownership or voting power
The reverse split follows stockholder approval on June 9, 2025, which authorized the board to implement a split ratio between 1-for-2 and 1-for-20 before June 9, 2026. This corporate action affects multiple registration statements on Forms S-3 and S-8 currently on file with the SEC.